| 2.23 0.04 (1.83%) | 09-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.61 | 1-year : | 3.05 |
| Resists | First : | 2.24 | Second : | 2.61 |
| Pivot price | 2.21  |
|||
| Supports | First : | 2.2 | Second : | 2.18 |
| MAs | MA(5) : | 2.23 | MA(20) : | 2.21 |
| MA(100) : | 2.12 |
MA(250) : | 2.18 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 83.3 | D(3) : | 83.3 |
| RSI | RSI(14): 59.1 | |||
| 52-week | High : | 3.65 | Low : | 1.28 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PRTK ] has closed below upper band by 28.4%. Bollinger Bands are 71.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 69 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.24 - 2.25 | 2.25 - 2.26 |
| Low: | 2.2 - 2.21 | 2.21 - 2.23 |
| Close: | 2.21 - 2.23 | 2.23 - 2.25 |
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Tue, 06 Jun 2023
Paratek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo Holdings - citybiz
Tue, 06 Jun 2023
Watkins Advises Gurnet Point Capital in Acquisition of Paratek Pharmaceuticals - Latham & Watkins LLP
Wed, 18 Jan 2023
Paratek/ Zai Lab antibiotic added for reimbursement in China (NASDAQ:PRTK) - Seeking Alpha
Mon, 12 Aug 2019
The 10 Top Penny Stocks to Watch Will Crush Wall Street's Negativity - Money Morning
Wed, 03 Oct 2018
Paratek gets second FDA approval in past 24 hours - The Business Journals
Tue, 02 Oct 2018
Paratek Announces FDA Approval of NUZYRA™ (Omadacycline) - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 57 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 11.6 (%) |
| Held by Institutions | 55 (%) |
| Shares Short | 2,640 (K) |
| Shares Short P.Month | 2,910 (K) |
| EPS | -1.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.52 |
| Profit Margin | -35.5 % |
| Operating Margin | -25.2 % |
| Return on Assets (ttm) | -18 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 34.9 % |
| Gross Profit (p.s.) | 1.73 |
| Sales Per Share | 3.08 |
| EBITDA (p.s.) | -0.78 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -2.01 |
| PEG Ratio | 0 |
| Price to Book value | -0.64 |
| Price to Sales | 0.72 |
| Price to Cash Flow | -5.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|